Business Context and Reporting Period
This Form 8-K, dated February 22, 2026, reports that Gilead Sciences, Inc. ("Gilead") entered into an Agreement and Plan of Merger to acquire Arcellx, Inc. ("Arcellx"). The transaction involves a tender offer followed by a merger, with Gilead's wholly-owned subsidiary, Ravens Sub, Inc., acting as the purchaser. The filing also notes the U.S. Food and Drug Administration's acceptance of Arcellx's Biologic License Application for its product candidate, anitocabtagene autoleucel (anito-cel).
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed acquisition rather than Gilead's operational financial results for a specific period.
- Offer Price: $115.00 per share in cash, net to the seller.
- Contingent Value Rights (CVRs): One CVR per share, representing a potential contingent cash payment of $5.00 per CVR.
- CVR Milestone: The $5.00 payment is triggered if cumulative worldwide sales of anito-cel exceed $6.0 billion on or before December 31, 2029.
- Termination Fee: Arcellx agreed to pay Gilead $260,000,000 if the agreement is terminated under specified circumstances, such as Arcellx accepting a superior offer.
- Support Agreements: Entered into with directors, officers, and certain investors controlling approximately 10.3% of Arcellx's outstanding shares.
Note: This filing does not provide Gilead's revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes and Conditions
The primary material change is the initiation of the acquisition process. The obligation to consummate the offer is subject to several conditions, including:
- Receipt of valid tenders representing more than 50% of outstanding shares.
- Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other foreign antitrust approvals.
- Absence of laws or orders prohibiting the transaction.
- Accuracy of representations and warranties and compliance with covenants.
The tender offer will remain open for a minimum of 20 business days from commencement.
Outlook, Risks, and Management Commentary
Management expects the transaction to be accretive to Gilead following FDA approval of anito-cel. The filing highlights significant risks and uncertainties, including:
- Regulatory Risk: Uncertainty regarding the timing or outcome of regulatory approvals for anito-cel and antitrust clearance for the merger.
- CVR Risk: The milestone for the $5.00 contingent payment may not be achieved by the expiration date, resulting in no payout.
- Integration Risk: Potential difficulties in integrating the businesses and realizing anticipated benefits.
- Transaction Risk: Possibility of competing offers or failure to satisfy closing conditions.
Forward-looking statements regarding the commercial launch of anito-cel and the transaction timeline are subject to these risks.
Key Facts for Investor Verification
- Verify the total consideration value ($115.00 cash + potential $5.00 CVR) against current market prices for Arcellx stock.
- Monitor the status of the Hart-Scott-Rodino waiting period and other antitrust approvals required for closing.
- Review the specific terms of the CVR Agreement (Annex III to the Merger Agreement) regarding the definition of "Sales" and the milestone calculation.
- Assess the likelihood of anito-cel achieving $6.0 billion in cumulative sales by December 31, 2029, given its current development stage.
- Check for the filing of the Tender Offer Statement on Schedule TO and Arcellx's Solicitation/Recommendation Statement on Schedule 14D-9 for detailed offer terms.